Braveheart Bio Tests a $1.35 Billion Valuation With Fidelity in the Book

SAN FRANCISCO, August 5, 2026: Braveheart Bio is asking IPO investors to put a roughly $1.35 billion post-offering equity value on one licensed heart drug, with a $75 million indication from Fidelity Management & Research giving the order book an unusually visible starting point. The company is poised to sell 18.75 million shares at $15 to $17 under the proposed Nasdaq symbol BRVE, a deal worth $300 million at the midpoint before a 2.81 million-share overallotment option.

The scale matters. At $16, the offering would produce an estimated $274.5 million of net proceeds and leave approximately 84.35 million shares outstanding when the prospectus’s post-March financing is included. That implies an equity value near $1.35 billion. Braveheart’s July 30 preliminary prospectus says Fidelity, acting for managed entities, has indicated interest in as much as $75 million at the IPO price. That amount would cover one-quarter of the base deal at the midpoint.

It is useful demand color, with a firm limit. Fidelity’s indication is non-binding, and the prospectus says it may buy more, fewer or no shares. IPOGrid reads the named interest as evidence that the book has an institutional anchor, not as a guarantee that pricing risk has disappeared. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are joint bookrunners, a broad syndicate for a clinical-stage issuer. Braveheart also reserved as much as 5% of the offering for directors, officers, employees and associated persons.

A single asset carries the valuation

Braveheart is built around BHB-1893, an oral cardiac myosin inhibitor for obstructive and non-obstructive hypertrophic cardiomyopathy. The company plans to start its global Phase 3 LIONHEART-HCM trial in obstructive disease in the second half of 2026 and NOBLEHEART-HCM in non-obstructive disease in the first half of 2027. More than 300 people had received the compound as of June 9, according to the prospectus.

The clinical pitch is differentiation on speed, dosing and cardiac safety. In a 42-patient Phase 2 obstructive HCM study, the filing reports an 86% complete gradient response at week 12 in one cohort and no treated patient with left ventricular ejection fraction below 50% during the core treatment period. Two patients later had transient readings below 50% in the extension study that resolved after dose changes. In non-obstructive HCM, Braveheart and Hengrui reported biomarker, remodeling and symptom improvements in a randomized Phase 2 study in May.

Those signals are the reason the IPO can be this large. The reviewer’s concern is how much validation public buyers are being asked to infer from a compact dataset. All completed BHB-1893 trials were designed, sponsored and conducted by Jiangsu Hengrui Pharmaceuticals, primarily in China, with one Phase 1 study in Australia. Braveheart says it did not participate in their design, conduct or oversight. Its global Phase 3 program therefore has to establish that the profile travels across populations and execution teams.

The company itself is young. Braveheart publicly launched in November 2025 with a $185 million Series A backed by Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences and Frazier Life Sciences. The speed from launch to IPO reflects a familiar late-stage biotech model: acquire ex-China rights to a clinically advanced molecule, capitalize a new development organization, then use public money to run global pivotal trials.

The proceeds fund two pivotal programs

The economics are straightforward but concentrated. Braveheart had $80.6 million of cash at March 31 and no product revenue. It lost $66.1 million in 2025, although $62.2 million of that was in-process research and development expense tied largely to acquiring the BHB-1893 license. The first quarter of 2026 produced a $14.3 million net loss, including $10.9 million of research and development expense.

At the midpoint, the company plans to direct about $90 million to the obstructive HCM Phase 3 program, $100 million to the non-obstructive program and $135 million to R&D personnel and overhead supporting both. Those allocations exceed estimated IPO net proceeds on their own, so existing cash is integral to the plan. Management says the combined capital should fund operations into 2029.

Our interpretation is that this is a substantial financing rather than a short bridge to one readout. It is designed to capitalize two global pivotal programs through completion, while absorbing the operating buildout around them. New investors would buy 27% of the post-offering shares at the midpoint but supply about 71% of the total cash consideration paid for all shares outstanding, according to the prospectus’s dilution table.

The license adds another layer. Braveheart paid Hengrui $32.5 million in cash and issued preferred stock originally valued at $32.5 million for rights outside Greater China. Hengrui can receive up to $23 million in technology-transfer and development milestones, as much as $1 billion in commercial milestones, plus tiered royalties. Braveheart also currently relies on Hengrui to manufacture BHB-1893 in China and has no qualified alternative supplier for the active ingredient or finished product.

That dependency is the cleanest caution flag in the deal. The financing may carry Braveheart into 2029, but capital alone does not solve technology transfer, manufacturing qualification or the need to reproduce Hengrui’s clinical results globally. The company’s August 3 Exchange Act registration moves BRVE closer to trading. The decisive signal now is where the IPO prices within the range, and how much of the visible Fidelity interest converts into an actual allocation.